ITK

Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

Retrieved on: 
Tuesday, May 10, 2022
CD73, CTCL, Securities and Exchange Commission (Philippines), Lymphoma, Allergy, Forward-looking statement, Immune system, Interim, Adenosine, Nasdaq, Stanford University School of Medicine, BTK, GLOBE, PK, Company, Neoplasm, ITK, Lymphocyte, Safety, Biomarker, Tumor microenvironment, Extranodal NK/T-cell lymphoma, nasal type, Phenotype, Leukemia, Patient, Immunity, Lymph, ATP, Review, Webcast, Security (finance), Cancer, Blood, Degenerative disease, NSCLC, T helper cell, Antigen presentation, T-cell lymphoma, R, A2A, Antigen, CEO, Research, NK, Pharmaceutical industry, Vaccine, LN, PTCL, Medicine, Corvus

BURLINGAME, Calif., May 10, 2022 (GLOBE NEWSWIRE) --  Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, is hosting an R&D Symposium today in New York City. During the event, which will also be available via webcast, the Company plans to provide updates on its three clinical programs: mupadolimab (anti-CD73), ciforadenant (adenosine 2A receptor antagonist) and CPI-818 (ITK inhibitor).

Key Points: 
  • BURLINGAME, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, is hosting an R&D Symposium today in New York City.
  • We have learned a tremendous amount about ITK, T cell biology and potential indications for this therapy from the development of CPI-818, said Richard A. Miller, M.D., Chief Executive Officer & President of Corvus Pharmaceuticals.
  • Angel Pharmaceuticals, our Chinese partner, is also enrolling patients, which we anticipate will help accelerate overall development timelines.
  • It will be hosted by Corvus President and CEO Richard A. Miller, M.D., and include speakers from Corvus as well as leading researchers:
    Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
CD73, Interim, Hematological Cancer Research Investment and Education Act, PK, Biomarker, PTCL, T-cell lymphoma, Safety, Extranodal NK/T-cell lymphoma, nasal type, Nivolumab, Immunity, ATP, Ipilimumab, Forward-looking statement, Immune system, Kidney cancer, Company, Pembrolizumab, Lymphocyte, Patient, Clinical trial, Neoplasm, Total, Large-cell lung carcinoma, RCC, Board of directors, U.S. Securities and Exchange Commission, Investment, Adenosine, BTK, Research, Leukemia, Monroe Dunaway Anderson, Security (finance), Survival, NSCLC, A2A, Antigen, NK, Board, Head, Lymphoma, Nasdaq, GLOBE, Autoimmunity, ITK, Tumor microenvironment, Cancer, Degenerative disease, Vaccine, Pharmaceutical industry, Corvus

BURLINGAME, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2022.

Key Points: 
  • BURLINGAME, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2022.
  • The Company will host an R&D Symposium on Tuesday, May 10, 2022 to provide an update on these clinical programs.
  • Corvus and its partner in China, Angel Pharmaceuticals, are enrolling patients with relapsed T cell lymphomas in Phase 1/1b trial evaluating single agent therapy with CPI-818.
  • The Companys results for the quarter ended March 31, 2022 are not necessarily indicative of its operating results for any future periods.

TEACHERS' PERSPECTIVES: WHY EDUCATORS ARE QUITTING AND WHAT BRANDS CAN DO TO HELP

Retrieved on: 
Monday, May 2, 2022
Parent, Sun, ITK, Mental health, National Education Association, Burn, Skin, K-12, Student, Mindfulness, Orthopathy, Organization, Public relations, Tutoring

CHARLESTON, S.C., May 2, 2022 /PRNewswire/ -- ITK Collective, a company that supports local communities by offering education, cause, and sampling campaigns from purpose-driven brands, recently surveyed its network of education professionals to gauge the needs of teachers and asked how brands can help provide essential resources. In honor of Teacher Appreciation Week May 2-6, ITK Collective shares important survey results on the demands of educators, the effects on their mental health, and how brands can help support local communities.

Key Points: 
  • In honor of Teacher Appreciation Week May 2-6, ITK Collective shares important survey results on the demands of educators, the effects on their mental health, and how brands can help support local communities.
  • Educators have fled the profession due to staffing shortages, burn out, a lack of support by their administration and stress.
  • Through its national network of grassroots influencers, ITK Collective is working to support teachers and students by directly connecting brands with educators.
  • As we celebrate Teacher Appreciation Week this week, ITK Collective is calling upon brands from all industries to step up and help fill the gaps our educators face, and help make their jobs easier.

Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York

Retrieved on: 
Tuesday, April 26, 2022
CEO, R, GLOBE, Patient, A2A, T-cell lymphoma, Nasdaq, Company, ITK, Extranodal NK/T-cell lymphoma, nasal type, CD73, Fine chemical, Corvus

BURLINGAME, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an R&D Symposium to provide an update on the Companys three clinical programs.

Key Points: 
  • BURLINGAME, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an R&D Symposium to provide an update on the Companys three clinical programs.
  • The event will be held on Tuesday, May 10, 2022, in New York City from 9:00 11:30 am Eastern Time.
  • The R&D symposium will cover the Companys pipeline programs: anti-CD73 (mupadolimab), adenosine 2A receptor antagonist (ciforadenant), and an update on ITK inhibitor (CPI-818) in T cell lymphomas.
  • Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Thursday, March 10, 2022
Large-cell lung carcinoma, Partnership, U.S. Securities and Exchange Commission, Survival, Autoimmunity, Adenosine, Degenerative disease, Leukemia, Immunity, Nivolumab, NSCLC, Safety, Biomarker, ITK, Company, Time management, T-cell lymphoma, Immune system, Total, A2A, Tumor microenvironment, GLOBE, Patient, Neoplasm, PK, Lymphocyte, Head, Clinical trial, Adult T-cell leukemia/lymphoma, ATP, Interim, Squamous cell carcinoma, Cancer, Extranodal NK/T-cell lymphoma, nasal type, Lymphoma, RECIST, Security (finance), Income, Forward-looking statement, Nasdaq, PTCL, Webcast, Monroe Dunaway Anderson, Research, Investment, Lung cancer, BTK, Board, Ipilimumab, Antigen, Board of directors, Kidney cancer, CD73, NK, RCC, Vaccine, Pharmaceutical industry, Lithium, Corvus

BURLINGAME, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • BURLINGAME, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021.
  • Results for the year ended December 31, 2020 included a $37.5 million gain from the deconsolidation of Angel Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2021 financial results.
  • The Companys results for the quarter and year ended December 31, 2021 are not necessarily indicative of its operating results for any future periods.

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Retrieved on: 
Thursday, March 3, 2022
Company, T-cell lymphoma, ITK, CD73, Webcast, Patient, A2A, Nasdaq, GLOBE, Corvus, Pharmaceutical industry

BURLINGAME, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 10, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2021 financial results.

Key Points: 
  • BURLINGAME, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 10, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2021 financial results.
  • The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) and using the conference ID 13727689.
  • The live webcast may be accessed via the investor relations section of the Corvus website.
  • A replay of the webcast will be available on Corvus' website for 90 days.

CANADA GOOSE PARTNERS WITH INUK DESIGNER, VICTORIA KAKUKTINNIQ, FOR THIRD PROJECT ATIGI COLLECTION

Retrieved on: 
Monday, January 24, 2022
Dark, Paris Fashion Week, Nature, Entrepreneurship, ITK, Human, NYSE, Tattoo, Collection, Toronto Fashion Week, Season, Health, Fashion, View, Awareness, Culture, Parent, Program, Year, Inuktitut, Education, GOOS, Water, Employment, Multimedia, Corporate social responsibility, Inuit, TSX, Inuvialuit Settlement Region, Parka, Murari Chand College, Life, Partnership, Woman, Fur clothing, Whaling, Canada goose, Arctic, Nunatsiavut, Inuit Nunangat

Kakuktinniq joins Canada Goose as Guest Designer, creating three limited-edition outerwear styles, benefiting Inuit communities across Canada through Inuit Tapiriit Kanatami (ITK), the national representational organization for Inuit in Canada.

Key Points: 
  • Kakuktinniq joins Canada Goose as Guest Designer, creating three limited-edition outerwear styles, benefiting Inuit communities across Canada through Inuit Tapiriit Kanatami (ITK), the national representational organization for Inuit in Canada.
  • Established in 2019, Project Atigi has evolved and expanded with each collection, while highlighting the heritage and craftsmanship of Inuit, the original parka makers.
  • The Project Atigi 2022 collection is available beginning today, January 24, in Canada Goose's stores around the world and online at canadagoose.com .
  • Canada Goose is inspired by relentless innovation and uncompromised craftsmanship, recognized as a leader for its Made in Canada commitment.

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

Retrieved on: 
Thursday, January 13, 2022
Biomarker, Forward-looking statement, Patient, Non-Hodgkin lymphoma, ITK, Antigen, NK, A2A, PK, Board of directors, COVID-19, Safety, NASDAQ, Extranodal NK/T-cell lymphoma, nasal type, TCL, HIV disease progression rates, Autoimmunity, T-cell lymphoma, GLOBE, Lymphoma, Society, Leukemia, U.S. Securities and Exchange Commission, ASH, BTK, CSCO, Company, CD73, PD, Chinese, Cancer, Interim, Security (finance), Degenerative disease, Trial of the century, Board, Investment, Fine chemical, Pharmaceutical industry, Vaccine, Corvus

BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b clinical trial of Corvus small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China.

Key Points: 
  • BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b clinical trial of Corvus small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China.
  • There is a significant opportunity to address unmet clinical need in China, where TCL are more common than in North America.
  • Corvus co-founded Angel Pharma to develop its pipeline in greater China and currently holds an equity stake of 49.7% in the company.
  • Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize CPI-818 in greater China and is responsible for all expenses related to its development in China.

New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

Retrieved on: 
Monday, December 13, 2021
T-cell lymphoma, Forward-looking statement, U.S. Securities and Exchange Commission, Gastrointestinal tract, NK, Lymphatic system, Poster, Company, Doctor of Philosophy, ITK, Biomarker, CD73, COVID-19, Time, Haematopoietic system, NASDAQ, Survival, Sickle cell disease, Pharmacokinetics, Memorial Sloan Kettering Cancer Center, Liver, Safety, Patient, Leukemia, Security (finance), Steroid, Bone marrow, Hemoglobinopathy, A2A, Immunodeficiency, MD, GLOBE, ASH, Interim, Division, Hematopoietic stem cell transplantation, Antigen, Skin, Mouse, Society, Head, Pharmaceutical industry, Vaccine, Degenerative disease, Corvus, GVHD

The data will be presented today in a poster at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition.

Key Points: 
  • The data will be presented today in a poster at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition.
  • Bone marrow transplantation is a potentially curative therapy for patients with a variety of blood disorders, including blood cancers, certain solid cancers, hemoglobinopathies such as sickle cell disease, and immune deficiencies.
  • Recipient mice were pre-conditioned by having their bone marrow ablated with high dose radiation, and then received an allogeneic bone marrow transplantation.
  • This preclinical data suggests that ITK inhibition with CPI-818 has the potential to be a novel agent that could prevent or treat aGVHD.

Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 10, 2021
A2A, T-cell lymphoma, ITK, NASDAQ, Conference, Company, GLOBE, CD73, Webcast, Patient, Vaccine

BURLINGAME, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies London Healthcare Conference, which is taking place November 16-19, 2021.

Key Points: 
  • BURLINGAME, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies London Healthcare Conference, which is taking place November 16-19, 2021.
  • A webcast of the presentation will be available via the investor relations section of the Corvus website for 30 days following the event.
  • Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
  • Corvus lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies.